Department of Cardiology, Cochin Hospital, Hôpitaux Universitaire Paris Centre, Assistance Publique des Hôpitaux de Paris, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France; INSERM U970, Paris Cardiovascular Research Center (PARCC), European Georges Pompidou Hospital, Paris, France.
Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France; Medical Intensive Care Unit, Cochin Hospital, Hôpitaux Universitaire Paris Centre, Assistance Publique des Hôpitaux de Paris, Paris, France.
Resuscitation. 2019 Dec;145:83-90. doi: 10.1016/j.resuscitation.2019.10.022. Epub 2019 Nov 1.
Data is scarce on hemorrhagic and thrombotic complications in patients with ST-elevation myocardial infarction (STEMI) associated with out-of-hospital cardiac arrest (OHCA).
This is a monocentric, retrospective study conducted from January 2012 to December 2017 in a tertiary university hospital, which serves as a cardiac arrest center for a large urban area. Over the study period, all consecutive patients who were treated with stent implantation for STEMI with or without OHCA were included. Baseline characteristics, treatments, hemorrhagic and thrombotic events were compared between STEMI patients with and without OHCA. Univariate and multivariate analysis were performed in order to identify predictors of 30-day mortality, occurrence of major bleeding (MB), and early stent thrombosis (ST).
A total of 549 patients treated for STEMI without OHCA and 146 patients for STEMI with OHCA were included. The incidence of definite ST and MB after coronary angioplasty was significantly higher in patients with OHCA (2.6% vs. 7.5%, p = 0.004 and 3.3% vs. 19.2%, p < 0.001, respectively). Independent predictors of MB in OHCA patients were anticoagulation therapy (HR = 3.11, 95%CI [1.22-7.98], p = 0.02) and the use of glycoprotein IIb/IIIa inhibitors (HR = 4.16, 95%CI [1.61-10.79], p = 0.003). Independent predictors of mortality in OHCA patients were age (HR = 1.05, 95%CI [1.02-1.09], p = 0.004) and ST (HR = 5.62, 95%CI [1.61-19.65], p = 0.007, with a protective effect of new anti-P2Y12 treatments (HR = 0.20, 95%CI [0.08-0.46], p < 0.001).
Patients treated for STEMI associated with OHCA are at higher-risk of ST and MB than those who did not experience cardiac arrest. In this subset of patients, prospective studies are needed to better evaluate the balance of thrombosis and hemorrhage.
关于伴有院外心脏骤停(OHCA)的 ST 段抬高型心肌梗死(STEMI)患者的出血和血栓并发症的数据很少。
这是一项单中心、回顾性研究,于 2012 年 1 月至 2017 年 12 月在一家三级大学医院进行,该医院是一个大城市的心脏骤停中心。在研究期间,所有接受支架植入治疗 STEMI 伴或不伴 OHCA 的连续患者均被纳入。比较 STEMI 伴或不伴 OHCA 患者的基线特征、治疗方法、出血和血栓事件。进行单变量和多变量分析以确定 30 天死亡率、主要出血(MB)和早期支架血栓形成(ST)的预测因素。
共纳入 549 例 STEMI 无 OHCA 患者和 146 例 STEMI 伴 OHCA 患者。OHCA 患者经血管成形术后明确 ST 和 MB 的发生率明显较高(2.6%比 7.5%,p=0.004 和 3.3%比 19.2%,p<0.001)。OHCA 患者发生 MB 的独立预测因素为抗凝治疗(HR=3.11,95%CI[1.22-7.98],p=0.02)和使用糖蛋白 IIb/IIIa 抑制剂(HR=4.16,95%CI[1.61-10.79],p=0.003)。OHCA 患者死亡的独立预测因素为年龄(HR=1.05,95%CI[1.02-1.09],p=0.004)和 ST(HR=5.62,95%CI[1.61-19.65],p=0.007),新型抗 P2Y12 治疗有保护作用(HR=0.20,95%CI[0.08-0.46],p<0.001)。
与 OHCA 相关的 STEMI 患者发生 ST 和 MB 的风险高于未发生心脏骤停的患者。在这部分患者中,需要前瞻性研究来更好地评估血栓形成和出血之间的平衡。